Cardiff Oncology gets FDA orphan drug designation for onvansertib in CMML
CRDF•The FDA granted orphan drug designation to Cardiff Oncology’s onvansertib for chronic myelomonocytic leukemia. The designation may provide up to seven years of market exclusivity upon regulatory approval.
1. FDA designation
The FDA granted orphan drug designation to Cardiff Oncology’s onvansertib for chronic myelomonocytic leukemia. The designation may provide up to seven years of market exclusivity upon regulatory approval.
